Riskpilot← Back to searchSign inGet full accessANGENOVO AS
ASActiveOrg 922693943Ullevålsveien 68, 0454 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20191 employees
Revenue 2024
NOK 433K
-90% vs 2023
EBITDA margin
-24.9%
-387% vs 2023
Equity ratio
49.3%
Financial strength
Net profit 2024
NOK -130K
-797% vs 2023
| Revenue | NOK 433K | -90% |
| EBITDA | NOK -108K | -387% |
| Net profit | NOK -130K | -797% |
| Total assets | NOK 337K | -25% |
| Equity | NOK 166K | -44% |
| Employees | 1 | — |
Legal name
ANGENOVO AS
Org number
922693943
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
2. mai 2019
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Huahong wang
Company purpose
Importere, eksportere, utvikle og selge kjemiske reagenser og instrumenter for biologisk og medisinsk forskning, og levere dataanalyse og konsulenttjenester.
Address
Ullevålsveien 68, 0454 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 461 | 3 802 | 4 885 | 4 274 | 433 |
| Staff expenses | −121 | −333 | −363 | −363 | −407 |
| EBITDA | 123 | 222 | −17 | 38 | −108 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 123 | 222 | −17 | 38 | −108 |
| Net financials | −0 | 2 | −0 | −14 | −24 |
| Profit before tax | 122 | 224 | −18 | 24 | −131 |
| Tax | 27 | 49 | −0 | 5 | −2 |
| Net profit | 95 | 175 | −17 | 19 | −130 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 163 | −567 | 500 | 451 | 337 |
| Equity | 125 | 295 | 277 | 296 | 166 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 38 | −862 | 223 | 155 | 171 |
| Total debt | 38 | −862 | 223 | 155 | 171 |
EBITDA margin
-24.9%
This company
15.8%
Market median
-258% vs market
20202024
Equity ratio
49.3%
This company
38.2%
Market median
+29% vs market
20202024
Return on equity
-78.1%
This company
18.4%
Market median
-524% vs market
20202024
Net profit margin
-30.0%
This company
8.1%
Market median
-470% vs market
20202024
Asset turnover
1.28×
This company
1.12×
Market median
+14% vs market
20202024
Debt / equity
1.03×
This company
0.62×
Market median
-66% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
YG Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2025 | |
| Board of Directors | 2021 | |
| Board of Directors | 2024 | |
| Chairman | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ANGENOVO AS 
Primebio Holding AsBoard members of ANGENOVO AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Yanwu Guo | Chief Executive Officer | 0 companies |
| Amit Kumar Sharma | Board of Directors | 0 companies |
| Chunlin Shi | Board of Directors | 0 companies |
| Hannah Huahong Wang | Board of Directors | 0 companies |
| Huahong Wang | Chairman | 0 companies |